SG10201912858VA - Antisense nucleic acids - Google Patents
Antisense nucleic acidsInfo
- Publication number
- SG10201912858VA SG10201912858VA SG10201912858VA SG10201912858VA SG10201912858VA SG 10201912858V A SG10201912858V A SG 10201912858VA SG 10201912858V A SG10201912858V A SG 10201912858VA SG 10201912858V A SG10201912858V A SG 10201912858VA SG 10201912858V A SG10201912858V A SG 10201912858VA
- Authority
- SG
- Singapore
- Prior art keywords
- nucleic acids
- antisense nucleic
- antisense
- acids
- nucleic
- Prior art date
Links
- 230000000692 anti-sense effect Effects 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014124157 | 2014-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912858VA true SG10201912858VA (en) | 2020-02-27 |
Family
ID=54935505
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201610130VA SG11201610130VA (en) | 2014-06-17 | 2015-06-16 | Antisense nucleic acids |
| SG10201912858VA SG10201912858VA (en) | 2014-06-17 | 2015-06-16 | Antisense nucleic acids |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201610130VA SG11201610130VA (en) | 2014-06-17 | 2015-06-16 | Antisense nucleic acids |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US9840706B2 (fr) |
| EP (2) | EP3159409B1 (fr) |
| JP (5) | JP6208349B2 (fr) |
| KR (1) | KR102335810B1 (fr) |
| CN (2) | CN106661577B (fr) |
| AU (3) | AU2015277924B2 (fr) |
| BR (2) | BR112016029369B1 (fr) |
| CA (1) | CA2951221A1 (fr) |
| CO (1) | CO2017000357A2 (fr) |
| CY (1) | CY1122462T1 (fr) |
| DK (1) | DK3159409T3 (fr) |
| ES (1) | ES2765463T3 (fr) |
| HR (1) | HRP20200042T1 (fr) |
| HU (1) | HUE047502T2 (fr) |
| IL (1) | IL249574B (fr) |
| LT (1) | LT3159409T (fr) |
| MX (2) | MX2016016526A (fr) |
| MY (1) | MY194170A (fr) |
| PH (1) | PH12016502501A1 (fr) |
| PL (1) | PL3159409T3 (fr) |
| PT (1) | PT3159409T (fr) |
| RS (1) | RS59764B1 (fr) |
| RU (1) | RU2695430C2 (fr) |
| SG (2) | SG11201610130VA (fr) |
| SI (1) | SI3159409T1 (fr) |
| TW (2) | TWI721461B (fr) |
| UA (1) | UA121117C2 (fr) |
| WO (1) | WO2015194520A1 (fr) |
| ZA (1) | ZA201700142B (fr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2765463T3 (es) * | 2014-06-17 | 2020-06-09 | Nippon Shinyaku Co Ltd | Acido nucleico antisentido para usar en el tratamiento de la distrofia muscular de Duchenne |
| CN108026531B (zh) | 2015-09-15 | 2021-09-14 | 日本新药株式会社 | 反义核酸 |
| US10563199B2 (en) * | 2015-09-16 | 2020-02-18 | Nippon Shinyaku Co., Ltd. | Antisense nucleic acid for treating amyotrophy |
| IL295755A (en) | 2015-10-09 | 2022-10-01 | Wave Life Sciences Ltd | Oligonucleotide preparations and methods thereof |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| US20190262375A1 (en) | 2016-06-30 | 2019-08-29 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
| ES2980686T3 (es) | 2016-12-19 | 2024-10-02 | Sarepta Therapeutics Inc | Conjugados de oligómero de omisión de exones para distrofia muscular |
| KR20240006057A (ko) | 2016-12-19 | 2024-01-12 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체 |
| EP3554553B1 (fr) | 2016-12-19 | 2022-07-20 | Sarepta Therapeutics, Inc. | Conjugués oligomère de sauts d'exons pour la dystrophie musculaire |
| CN110381980A (zh) | 2017-01-06 | 2019-10-25 | 艾维迪提生物科学有限责任公司 | 核酸-多肽组合物以及诱导外显子跳读的方法 |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| JP2020537497A (ja) * | 2017-09-22 | 2020-12-24 | アビディティー バイオサイエンシーズ，インク． | エクソンスキッピングを誘発する核酸ポリペプチド組成物と方法 |
| EA201991450A1 (ru) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| MX2020005860A (es) | 2017-12-06 | 2020-09-09 | Avidity Biosciences Inc | Composiciones y metodos de tratamiento de atrofia muscular y distrofia miotonica. |
| US10765760B2 (en) | 2018-05-29 | 2020-09-08 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| MX2021001281A (es) | 2018-08-02 | 2021-07-15 | Dyne Therapeutics Inc | Complejos dirigidos a músculos y sus usos para el tratamiento de distrofinopatías. |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CA3108289A1 (fr) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Complexes de ciblage musculaire et leurs utilisations pour le traitement de la dystrophie musculaire facio-scapulo-humerale |
| AU2019370937A1 (en) * | 2018-11-02 | 2021-05-27 | Biomarin Technologies B.V. | Bispecific antisense oligonucleotides for dystrophin exon skipping |
| JP2023537798A (ja) | 2020-03-19 | 2023-09-06 | アビディティー バイオサイエンシーズ，インク． | 顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法 |
| US20230193282A1 (en) | 2021-04-30 | 2023-06-22 | Sarepta Therapeutics, Inc. | Treatment methods for muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| EP4389893A1 (fr) | 2021-08-21 | 2024-06-26 | Takeda Pharmaceutical Company Limited | Conjugué peptide-médicament liant le récepteur de la transferrine humaine |
| CA3229962A1 (fr) | 2021-08-24 | 2023-03-02 | Peptidream Inc. | Conjugue anticorps-peptide se liant au recepteur de la transferrine humaine |
| KR20240055874A (ko) | 2021-09-16 | 2024-04-29 | 어비디티 바이오사이언시스 인크. | 안면견갑상완 근이영양증을 치료하는 조성물 및 방법 |
| CN118488959A (zh) | 2021-12-27 | 2024-08-13 | 日本新药株式会社 | 低聚核酸化合物的制造方法 |
| EP4215614A1 (fr) | 2022-01-24 | 2023-07-26 | Dynacure | Thérapie de combinaison pour maladies liées à la dystrophine |
| EP4230196A1 (fr) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Composés à utiliser dans le traitement des dystrophinopathies |
| WO2023168427A1 (fr) | 2022-03-03 | 2023-09-07 | Yale University | Compositions et procédés d'administration de polynucléotides thérapeutiques pour saut d'exon |
| IL315280A (en) | 2022-03-17 | 2024-10-01 | Sarepta Therapeutics Inc | Morpholino phosphorodiamidate oligomer conjugates |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU655164B2 (en) | 1989-12-20 | 1994-12-08 | Antivirals Inc. | Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages |
| JP2924179B2 (ja) | 1993-02-19 | 1999-07-26 | 日本新薬株式会社 | グリセロール誘導体，デバイス及び医薬組成物 |
| FR2705361B1 (fr) * | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| ES2554660T3 (es) | 2002-11-25 | 2015-12-22 | Masafumi Matsuo | Fármacos de ácido nucleico ENA que modifican el corte y empalme en precursores de ARNm |
| WO2004083432A1 (fr) | 2003-03-21 | 2004-09-30 | Academisch Ziekenhuis Leiden | Modulation de la reconnaissance d'exons dans le pre-arnm par interference avec la structure d'arn secondaire |
| EP3808845A1 (fr) | 2004-06-28 | 2021-04-21 | The University Of Western Australia | Oligonucléotides antisens pour induire l'omission de l'exon et leurs procédés d'utilisation |
| EP1857548A1 (fr) | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Procédé et moyen permettant d'induire un saut d'exon |
| JP5143450B2 (ja) * | 2007-03-14 | 2013-02-13 | 斉 大戸 | Ｈｌａ−ｂローカスにおける新規アリル |
| CA2704049A1 (fr) * | 2007-10-26 | 2009-04-30 | Academisch Ziekenhuis Leiden | Moyens et procedes pour contrebalancer des troubles musculaires |
| CN101861318A (zh) | 2007-11-15 | 2010-10-13 | Avi生物制药公司 | 合成吗啉代低聚物的方法 |
| EP2119783A1 (fr) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Procédé pour l'omission efficace de l'exon (44) dans la dystrophie musculaire de Duchenne et moyens connexes |
| US8084601B2 (en) | 2008-09-11 | 2011-12-27 | Royal Holloway And Bedford New College Royal Holloway, University Of London | Oligomers |
| US8871918B2 (en) * | 2008-10-24 | 2014-10-28 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for DMD |
| AU2010239779A1 (en) | 2009-04-24 | 2011-11-17 | Prosensa Technologies B.V. | Oligonucleotide comprising an inosine for treating DMD |
| KR102581868B1 (ko) | 2009-11-12 | 2023-10-04 | 더 유니버시티 오브 웨스턴 오스트레일리아 | 안티센스 분자 및 이를 이용한 질환 치료방법 |
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| CN103501793A (zh) * | 2011-02-08 | 2014-01-08 | 夏洛特-梅克伦堡医院(商业用名:卡罗来纳保健系统) | 反义寡核苷酸 |
| CN110055243B (zh) * | 2011-12-28 | 2024-03-26 | 日本新药株式会社 | 反义核酸 |
| CN104203289B (zh) | 2012-01-27 | 2020-11-03 | 比奥马林技术公司 | 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸 |
| JP6460983B2 (ja) * | 2012-07-03 | 2019-01-30 | バイオマリン テクノロジーズ ベー．フェー． | 筋ジストロフィー患者の治療のためのオリゴヌクレオチド |
| JP2014124157A (ja) | 2012-12-27 | 2014-07-07 | Nihon Cornstarch Corp | コーヒー飲料 |
| SI3118311T1 (sl) | 2014-03-12 | 2019-05-31 | Nippon Shinyaku Co., Ltd. | Protismiselna nukleinska kislina |
| ES2765463T3 (es) * | 2014-06-17 | 2020-06-09 | Nippon Shinyaku Co Ltd | Acido nucleico antisentido para usar en el tratamiento de la distrofia muscular de Duchenne |
-
2015
- 2015-06-16 ES ES15810097T patent/ES2765463T3/es active Active
- 2015-06-16 EP EP15810097.4A patent/EP3159409B1/fr active Active
- 2015-06-16 WO PCT/JP2015/067238 patent/WO2015194520A1/fr active Application Filing
- 2015-06-16 HU HUE15810097A patent/HUE047502T2/hu unknown
- 2015-06-16 SG SG11201610130VA patent/SG11201610130VA/en unknown
- 2015-06-16 SG SG10201912858VA patent/SG10201912858VA/en unknown
- 2015-06-16 LT LTEP15810097.4T patent/LT3159409T/lt unknown
- 2015-06-16 CN CN201580037016.2A patent/CN106661577B/zh active Active
- 2015-06-16 AU AU2015277924A patent/AU2015277924B2/en active Active
- 2015-06-16 RU RU2017101172A patent/RU2695430C2/ru active
- 2015-06-16 SI SI201531057T patent/SI3159409T1/sl unknown
- 2015-06-16 DK DK15810097.4T patent/DK3159409T3/da active
- 2015-06-16 MX MX2016016526A patent/MX2016016526A/es active IP Right Grant
- 2015-06-16 BR BR112016029369-0A patent/BR112016029369B1/pt active IP Right Grant
- 2015-06-16 EP EP19208809.4A patent/EP3660154A1/fr active Pending
- 2015-06-16 CN CN202010289118.6A patent/CN111575282B/zh active Active
- 2015-06-16 TW TW108121749A patent/TWI721461B/zh active
- 2015-06-16 MY MYPI2016704648A patent/MY194170A/en unknown
- 2015-06-16 KR KR1020167036291A patent/KR102335810B1/ko active IP Right Grant
- 2015-06-16 TW TW104119378A patent/TWI666317B/zh active
- 2015-06-16 BR BR122020020864-3A patent/BR122020020864B1/pt active IP Right Grant
- 2015-06-16 PL PL15810097T patent/PL3159409T3/pl unknown
- 2015-06-16 PT PT158100974T patent/PT3159409T/pt unknown
- 2015-06-16 UA UAA201700424A patent/UA121117C2/uk unknown
- 2015-06-16 US US15/314,535 patent/US9840706B2/en active Active
- 2015-06-16 CA CA2951221A patent/CA2951221A1/fr active Pending
- 2015-06-16 RS RS20200002A patent/RS59764B1/sr unknown
- 2015-06-16 JP JP2016529346A patent/JP6208349B2/ja active Active
-
2016
- 2016-12-13 MX MX2020004417A patent/MX2020004417A/es unknown
- 2016-12-14 PH PH12016502501A patent/PH12016502501A1/en unknown
- 2016-12-14 IL IL249574A patent/IL249574B/en active IP Right Grant
-
2017
- 2017-01-06 ZA ZA2017/00142A patent/ZA201700142B/en unknown
- 2017-01-16 CO CONC2017/0000357A patent/CO2017000357A2/es unknown
- 2017-08-15 US US15/677,071 patent/US11193125B2/en active Active
- 2017-09-06 JP JP2017171127A patent/JP6701139B2/ja active Active
-
2020
- 2020-01-08 CY CY20201100011T patent/CY1122462T1/el unknown
- 2020-01-10 HR HRP20200042TT patent/HRP20200042T1/hr unknown
- 2020-05-01 JP JP2020080938A patent/JP7041879B2/ja active Active
-
2021
- 2021-05-25 AU AU2021203383A patent/AU2021203383B2/en active Active
- 2021-11-02 US US17/517,006 patent/US12060556B2/en active Active
-
2022
- 2022-03-01 JP JP2022030557A patent/JP2022082539A/ja not_active Withdrawn
-
2023
- 2023-12-26 JP JP2023218761A patent/JP2024023899A/ja active Pending
-
2024
- 2024-02-27 AU AU2024201290A patent/AU2024201290A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190235T1 (hr) | Antisensna nukleinska kiselina | |
| ZA201700142B (en) | Antisense nucleic acids | |
| DK3134131T3 (en) | Nucleic acid vaccines | |
| IL258065B (en) | Nucleic acids against the coding strand | |
| GB201503408D0 (en) | Oligonucleotides | |
| IL257500A (en) | Altered cullin1 gene | |
| GB201517241D0 (en) | DNA modification | |
| SG11201700652PA (en) | Modified antimir-138 oligonucleotides | |
| GB2524076B8 (en) | Improved Heater | |
| GB201516505D0 (en) | Antisense oligonucleotides | |
| GB201508733D0 (en) | Antisense oligonucleotides | |
| GB201407865D0 (en) | Nucleases | |
| GB201403353D0 (en) | Novel oligonucleotides | |
| GB201403087D0 (en) | Novel oligonucleotides | |
| GB201403359D0 (en) | Nucleic acids and uses thereof | |
| GB201403360D0 (en) | Nucleic acids and uses thereof |